Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by ready2go1on Sep 10, 2012 6:16pm
276 Views
Post# 20344315

PCA3 is the news

PCA3 is the news

just a few quick comments; Pca3 is what will move this stock... how they have handled GCC was a mistake from the start, the lab was a big expense and they had other options but it was a positive they were relieved from that when Signal came on. I look for Signal to pay them in full or CUR will find a new company to partner with which will be a positive down the road. All of this still does not excuse how badly this was handled on the conference call.

I mentioned this briefly in a past post; the revenue that CUR posts from pca3 is so far behind that it is irrevelant, it is meaningless. They did a poor job on the call other than to say that it is Now 6 months behind. Thats prior to FDA approval. Hologic spoke about updates in November and I hope that they are able to clear things up at that time.

For now, we are all in the dark, and thats why we are seeing the selling, fear of the unknown. (CUR is also in the dark) What is known is that pca3 is being used on a regular basis at Leading Institutions here in the U.S. All one has to do is look at the top rated hospitals in urology and look at their websites.

Revenue will show a spike at some point once we get caught up, but my fear by that time is that CUR will be acquired at a much lower price than deserved.

I don't blame anyone for selling because this is frustrating and has been for a long time, but the studies don't lie and Hologic will announce their plans at some point this year and we will bounce back to FDA approval levels.

<< Previous
Bullboard Posts
Next >>